Press Releases Keyword Search Year None20202019201820172016201520142013 September 11, 2020 Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference September 4, 2020 Editas Medicine to Participate in Upcoming Investor Conferences August 24, 2020 Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease August 6, 2020 Editas Medicine Announces Second Quarter 2020 Results and Update August 6, 2020 Editas Medicine Regains Full Global Rights to Ocular Medicines July 29, 2020 Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline July 27, 2020 Editas Medicine Appoints Gad Berdugo as Chief Business Officer July 23, 2020 Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update July 7, 2020 Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing June 26, 2020 Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
September 11, 2020 Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference
August 24, 2020 Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease
July 29, 2020 Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
July 23, 2020 Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update
July 7, 2020 Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing
June 26, 2020 Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares
